Oryzon Genomics (ORY.MC) Stock Price
Oryzon Genomics Price
Revenue at Oryzon Genomics has contracted by 46.8% per year over the past 5 years to 20,000.00 EUR. For Oryzon Genomics, the net margin of -26,000.0% is down versus -4,500.0% a few years ago. The consensus 12-month price target for Oryzon Genomics is 5.71 EUR, about 105.3% above where the stock trades today. Of 10 analysts, 9 rate the stock a buy — an overall Buy consensus. The stock trades about 4% above its 52-week low.
Oryzon Genomics stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Oryzon Genomics over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Oryzon Genomics stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Oryzon Genomics's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Oryzon Genomics Price |
|---|---|
| 9/14/2026 | 2.78 EUR |
| 9/11/2026 | 2.79 EUR |
| 9/10/2026 | 2.79 EUR |
| 9/9/2026 | 2.79 EUR |
| 9/8/2026 | 2.81 EUR |
| 9/7/2026 | 2.78 EUR |
| 9/4/2026 | 2.81 EUR |
| 9/3/2026 | 2.81 EUR |
| 9/2/2026 | 2.80 EUR |
| 9/1/2026 | 2.79 EUR |
| 8/31/2026 | 2.80 EUR |
| 8/28/2026 | 2.85 EUR |
| 8/27/2026 | 2.84 EUR |
| 8/26/2026 | 2.84 EUR |
| 8/25/2026 | 2.86 EUR |
| 8/21/2026 | 2.85 EUR |
| 8/20/2026 | 2.79 EUR |
| 8/19/2026 | 2.83 EUR |
| 8/18/2026 | 2.86 EUR |
| 8/17/2026 | 2.90 EUR |
| 8/14/2026 | 2.89 EUR |
| 8/13/2026 | 2.90 EUR |
| 8/12/2026 | 2.90 EUR |
| 8/11/2026 | 2.90 EUR |
| 8/10/2026 | 2.90 EUR |
| 8/7/2026 | 2.91 EUR |
| 8/6/2026 | 2.92 EUR |
| 8/5/2026 | 2.93 EUR |
| 8/4/2026 | 2.94 EUR |
| 7/31/2026 | 2.88 EUR |
Oryzon Genomics Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Oryzon Genomics Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEM EUR |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEM EUR |
| EBITM EUR |
| EBIT MARGIN% |
| NET INCOMEM EUR |
| NET INCOME GROWTH% |
| SHARESM |
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025e | 2026e | 2027e | 2028e | 2029e | 2030e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4.00 | – | – | – | – | – | – | – | – | – | 12.00 | 8.00 | 27.00 | 113.00 | 248.00 | 345.00 |
| -69.23 | – | – | – | – | – | – | – | – | – | – | -33.33 | 237.50 | 318.52 | 119.47 | 39.11 |
| 50.00 | – | – | – | – | – | – | – | – | – | -8.33 | -12.50 | -3.70 | -0.88 | -0.40 | -0.29 |
| 2.00 | -1.00 | -1.00 | -1.00 | -1.00 | -1.00 | -3.00 | -2.00 | -1.00 | -1.00 | -1.00 | -1.00 | -1.00 | -1.00 | -1.00 | -1.00 |
| – | -4.00 | -4.00 | -2.00 | -3.00 | -4.00 | -7.00 | -5.00 | -4.00 | -4.00 | – | -6.00 | 2.00 | 80.00 | 149.00 | 209.00 |
| – | – | – | – | – | – | – | – | – | – | – | -75.00 | 7.41 | 70.80 | 60.08 | 60.58 |
| – | -5.00 | -5.00 | -1.00 | -3.00 | -3.00 | -4.00 | -4.00 | -3.00 | -3.00 | – | -6.00 | – | 22.00 | 102.00 | 143.00 |
| – | – | – | -80.00 | 200.00 | – | 33.33 | – | -25.00 | – | – | – | – | – | 363.64 | 40.20 |
| 27.49 | 27.72 | 33.48 | 38.45 | 45.49 | 52.76 | 52.76 | 55.29 | 60.88 | 64.75 | 64.75 | 64.75 | 64.75 | 64.75 | 64.75 | 64.75 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Oryzon Genomics generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Oryzon Genomics retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Oryzon Genomics's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Oryzon Genomics has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Oryzon Genomics's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Oryzon Genomics stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Oryzon Genomics Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Oryzon Genomics business model & stock analysis
Oryzon Genomics SWOT Analysis
Strengths
Oryzon Genomics SA has several key strengths that contribute to its competitive advantage:
- Strong research and development capabilities, enabling the company to innovate and develop new products.
- A solid portfolio of intellectual property rights, providing protection for its discoveries and technologies.
- Well-established partnerships and collaborations with academic and industry experts, fostering knowledge exchange and opportunities for growth.
- Robust financial position, allowing investment in cutting-edge technologies and expansion into new markets.
- Successful track record in achieving regulatory approvals and commercializing products.
Weaknesses
Despite its strengths, Oryzon Genomics SA also faces certain weaknesses:
- Reliance on a limited number of key products or pipeline candidates, posing risks associated with dependency.
- Dependency on collaborations and partnerships for research and development, potentially limiting control over decision-making processes.
- Significant investments required for product development and clinical trials, placing financial strain on the company.
- Limited marketing and commercialization capabilities, potentially affecting market penetration and revenue generation.
- Susceptibility to regulatory changes and uncertainties within the biotechnology industry.
Opportunities
Oryzon Genomics SA can capitalize on the following opportunities in the market:
- Growing global demand for innovative therapies and personalized medicine, opening up new revenue streams.
- Expansion into emerging markets with favorable regulatory environments, facilitating market entry and growth.
- Potential collaborations and partnerships with pharmaceutical giants, providing access to additional resources and expertise.
- Advancements in technology and data analytics, enabling improved therapeutic targeting and personalized treatment options.
- Increased focus on neurodegenerative diseases and mental health, aligning with Oryzon's areas of expertise.
Threats
Oryzon Genomics SA should be aware of the following threats in the competitive landscape:
- Intense competition from other biotechnology companies and established pharmaceutical players.
- Stringent regulatory requirements and complex approval processes, leading to potential delays and increased costs.
- Rapidly evolving technological advancements, necessitating continuous investment to stay ahead.
- Intellectual property challenges and potential infringements from competitors.
- Economic downturns and market volatility affecting funding and investment opportunities.
Oryzon Genomics Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
Oryzon Genomics historical P/E ratio, EBIT multiple, and P/S ratio
Oryzon Genomics annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down Oryzon Genomics's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in Oryzon Genomics's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare Oryzon Genomics's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Oryzon Genomics shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Current Oryzon Genomics forecasts and price targets in September 2026
Analyst Price Targets 2026Oryzon Genomics Earnings Estimates & Surprises
| Date | EPS estimate | EPS Actual | Revenue Estimate | Price reaction | Quarterly report |
|---|---|---|---|---|---|
| 11/6/2026 | -0.07EUR | - | -EUR | - | 2026 Q3 |
| 7/27/2026 | -0.06EUR | -0.00EUR | -EUR | - | 2026 Q2 |
| 5/14/2026 | -0.02EUR | -0.02EUR | 2.00 MEUR | - | 2026 Q1 |
| 2/27/2026 | -0.03EUR | -0.02EUR | 1.90 MEUR | - | 2025 Q4 |
| 11/7/2025 | -0.01EUR | -0.01EUR | 1.40 MEUR | - | 2025 Q3 |
| 8/4/2025 | -0.03EUR | 0.00EUR | 1.40 MEUR | - | 2025 Q2 |
| 2/27/2025 | -0.02EUR | -0.02EUR | 950,000.00EUR | - | 2024 Q4 |
| 10/24/2024 | -0.02EUR | -0.02EUR | 950,000.00EUR | - | 2024 Q3 |
| 7/31/2024 | -0.01EUR | 0.00EUR | -EUR | - | 2024 Q2 |
| 5/6/2024 | -0.03EUR | -0.02EUR | -EUR | - | 2024 Q1 |
EESG©
Eulerpool ESG Scorecard© for the Oryzon Genomics stock
EEnvironment
Environment
SSocial
Social
GGovernance (Corporate Governance)
Governance (Corporate Governance)
The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.
Oryzon Genomics shareholder structure
| % | Name |
|---|---|
10.88003% | |
7.69928% | |
5.27293% | |
3.99963% | |
0.15506% | |
0.10520% |
Oryzon Genomics Beneficial Ownership Filings (SEC 13D/G)
Oryzon Genomics Executives and Management Board
17 members · avg. age 66 · 24 % women
Don Carlos Manuel Buesa Arjol
Executive Chairman of the Board, Chief Executive Officer · since 2002
478,000.00 EUR
Management
Don Enric Rello Condomines
Chief Financial and Operating Officer
Don Jordi Xaus Pey
Chief Scientific Officer
Don Xavier Perpinya Ribera
Chief Internal Audit and Compliance Officer
Don Michael Ropacki
Chief Medical Officer - CNS
Board of Directors
Don Manuel Oscar Lopez-Figueroa
Lead Independent Director
Don Antonio Fornieles Melero
Independent Director
Don Ramon Adell Ramon (67)
Independent Director
Dna. Isabel Aguilera Navarro (64)
Independent Director
Dna. Sonia Paloma Gutierrez Bezon
Director - Clinical Operations
Don Emili Torrell Cortada
Director - Business Development
Oryzon Genomics Supply Chain
Frequently asked questions about Oryzon Genomics
The business model of Oryzon Genomics SA revolves around the development and commercialization of innovative epigenetic therapies. As a biopharmaceutical company, Oryzon focuses on the research and discovery of new drugs to treat diseases associated with altered gene expression. By targeting specific epigenetic marks, they aim to regulate gene activity and restore normal cellular function. Oryzon Genomics SA collaborates with academic institutions and pharmaceutical companies to advance their therapies through preclinical and clinical development stages. With a focus on epigenetics, Oryzon strives to provide novel therapeutic solutions for diseases such as cancer, neurological disorders, and autoimmune conditions.
Oryzon Genomics SA is primarily active in the biotechnology industry.
Some of the main competitors of Oryzon Genomics SA in the market include other companies in the field of biotechnology and pharmaceuticals. These can include companies like Roche Holding AG, Novartis AG, and Amgen Inc.
Oryzon Genomics SA is a biopharmaceutical company specializing in epigenetics and precision medicine. Founded in 2000, the Spanish-based company emerged from a joint initiative of scientists and researchers from the University of Barcelona and the Spanish National Research Council. Oryzon Genomics focuses on the development of innovative therapies for serious diseases, such as cancer and neurological disorders, by modulating gene expression through epigenetic mechanisms. They employ cutting-edge technologies and have a robust pipeline of investigational drugs under development. Oryzon Genomics aims to bring novel and effective treatment options to patients and contribute to advancing the field of precision medicine.
Oryzon Genomics SA has achieved several significant milestones. The company successfully completed various clinical trials, including Phase II and Phase IIB studies, for its lead investigational drug, vafidemstat. They have also garnered positive results in these trials, demonstrating the drug's potential for the treatment of various neurological and psychiatric disorders. Oryzon Genomics SA has secured several partnerships and collaborations with renowned institutions and pharmaceutical companies to further advance their research and development efforts. They have also received important regulatory designations, such as Orphan Drug Designation from the U.S. FDA, further validating the potential of their innovative therapies.
Oryzon Genomics SA is primarily present in Spain and the United States.
Oryzon Genomics SA represents core values of innovation, integrity, and collaboration. This biopharmaceutical company is committed to advancing precision medicine through cutting-edge research and development. With a focus on epigenetics, Oryzon Genomics SA aims to discover and develop novel therapies for serious diseases such as cancer and neurodegenerative disorders. The company's corporate philosophy revolves around ethically transforming scientific knowledge into tangible solutions for patients worldwide. By fostering partnerships and leveraging its expertise, Oryzon Genomics SA strives to bring about meaningful advancements in the field of personalized medicine.
Analysts currently set an average price target of 7.33 EUR for the Oryzon Genomics stock (median: 5.71 EUR), implying +160.4 % versus the latest price. The consensus is based on 10 analyst ratings.
10 analysts currently rate the Oryzon Genomics stock: 9 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Oryzon Genomics to generate revenue of 8.99 M EUR and earnings per share of -0.10 EUR.
The Oryzon Genomics share (ORY.MC) is listed on 7 stock exchanges, including: London (0RDB.L), Frankfurt (ORN.F), München (ORN.MU), Düsseldorf (ORN.DU), Madrid (ORY.MC).
Oryzon Genomics SA is a biotechnology company specializing in the development of epigenetic-based therapies for neurodegenerative diseases and cancer. The company is headquartered in Spain and has been listed on the Madrid Stock Market since 2015. Oryzon Genomics SA's business model includes several divisions, each with a specific focus to achieve Oryzon's goal of providing innovative therapies for severe and chronic diseases. The main focus is on identifying enzymes involved in epigenetic changes that contribute to the onset of certain diseases. These enzymes are intended to serve as targets for the development of new drugs. The first division of Oryzon Genomics SA is the research and development of drugs. The company has various programs in the field of epigenetics focused on the development of therapeutics for severe diseases. This includes programs for Alzheimer's disease, multiple sclerosis, autism, depression, and various types of cancer. The company focuses on the discovery of new drug classes and works closely with academic institutions and pharmaceutical companies. Another important division of Oryzon is the Mechanism-of-Action (MOA) service. This service helps other pharmaceutical companies understand the mode of action of new drugs. Oryzon offers its service for the analysis of potential drug effectiveness and assists in identifying new therapeutic target structures. This is intended to enable other pharmaceutical companies to develop new drugs more quickly. The company also has a Clinical Development Unit that focuses on the clinical development of new drugs. In this division, data from animal studies and Phase I areas are used to test the efficacy and safety of compounds in clinical trials. The clinical development of drugs is a time-consuming and costly process, but it is also a crucial phase for the approval of a new drug. Another important area of Oryzon Genomics is its service business. Here, the company offers its expertise and experience in epigenetics to assist other pharmaceutical companies and academic institutions in the development of new drugs and diagnostics. The services offered include drug discovery services, analytical and preclinical services, molecular biology and epigenetic services, and assay development services. Finally, the company also offers products such as epigenetic kits and reagents for research. These products are intended to help scientists better understand the mechanisms of epigenetics and develop new therapeutic approaches. In summary, Oryzon Genomics SA's business model is focused on developing innovative therapies for severe and chronic diseases. The company identifies enzymes involved in epigenetic changes and uses them as targets for new drugs. The company has several divisions, including research and development, the MOA service, the Clinical Development Unit, and the service business. Oryzon Genomics SA also offers products such as epigenetic kits and reagents for research and strives to advance the development of new therapeutic approaches in epigenetics.
The expected revenue of Oryzon Genomics is 8.99 M EUR. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Oryzon Genomics is -6.51 M EUR. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Oryzon Genomics is currently -27.65. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Oryzon Genomics stock.
The price-to-sales ratio (P/S) of Oryzon Genomics is currently 20.04. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Oryzon Genomics stock.
The Eulerpool Quality Score for Oryzon Genomics is 2/10.
The ISIN of Oryzon Genomics is ES0167733015. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Oryzon Genomics is A2ACV2. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Oryzon Genomics is ORY.MC. The ticker symbol is used to trade Oryzon Genomics shares on the stock exchange.
Oryzon Genomics paid dividends every year for the past 0 years.
Oryzon Genomics is assigned to the 'Health' sector.
The dividends of Oryzon Genomics are distributed in EUR.
Oryzon Genomics stock
Oryzon Genomics Peer Group
Oryzon Genomics Ticker
Oryzon Genomics FIGI
All fundamentals and in-depth analysis of Oryzon Genomics
Our stock analysis for Oryzon Genomics stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Oryzon Genomics. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.